VICTOZA Drug Patent Profile

When do Victoza patents expire, and what generic alternatives are available?

Victoza is a drug marketed by Novo Nordisk Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-three patent family members in twenty-seven countries.

The generic ingredient in VICTOZA is liraglutide. There are seven drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the liraglutide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Victoza

A generic version of VICTOZA was approved as liraglutide by HIKMA on December 23^rd, 2024.

Summary for VICTOZA

International Patents:	63
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	126
Patent Applications:	6,329
Drug Prices:	Drug price information for VICTOZA
Drug Sales Revenues:	Drug sales revenues for VICTOZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VICTOZA
What excipients (inactive ingredients) are in VICTOZA?	VICTOZA excipients list
DailyMed Link:	VICTOZA at DailyMed

See drug prices for VICTOZA

See drug sales revenues for VICTOZA

Recent Clinical Trials for VICTOZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Chicago	Early Phase 1
Carmot Therapeutics, Inc.	Phase 1
Yale University	Phase 3

See all VICTOZA clinical trials

Pharmacology for VICTOZA

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Paragraph IV (Patent) Challenges for VICTOZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VICTOZA	Injection	liraglutide	18 mg/3 mL prefilled syringe	022341	1	2016-12-12

US Patents and Regulatory Information for VICTOZA

VICTOZA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes					Y
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes					Y

Expired US Patents for VICTOZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010

International Patents for VICTOZA

See the table below for patents covering VICTOZA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	197408
Australia	2265099
Australia	748277
Brazil	9906857
Canada	2305634	SERINGUE D'INJECTION (AN INJECTION SYRINGE)
China	1243578
China	1277558

Supplementary Protection Certificates for VICTOZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0944648	CA 2009 00041	Denmark
0944648	SPC034/2009	Ireland		SPC034/2009: 20101001, EXPIRES: 20220821
0944648	SPC/GB09/058	United Kingdom		PRODUCT NAME: LIRAGLUTIDE; REGISTERED: UK EU/1/09/529/001 20090630
0944648	09C0054	France		PRODUCT NAME: LIRAGLUTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/529/001 DU 20090630; REGISTRATION NO/DATE AT EEC: EU/1/09/529/001 DU 20090630
0944648	C00944648/01	Switzerland		PRODUCT NAME: LIRAGLUTID; REGISTRATION NO/DATE: SWISSMEDIC 59329 11.12.2009
2209800	C300698	Netherlands		PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918
2209800	1490067-4	Sweden		PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918

Last updated: July 22, 2026

Market dynamics and financial trajectory for VICTOZA (liraglutide): sales trends, share shifts, exclusivity risk, and competitive outlook

VICTOZA (liraglutide) remains a high-share GLP-1 franchise product in select markets, but its financial trajectory has been pressured by faster-growing GLP-1 competitors and by the maturing of its core exclusivity window. Near-term economics are driven by (1) how quickly prescribers switch to newer agents with higher efficacy and/or lower dosing burden, (2) payer formulary design that steers use toward preferred GLP-1s, and (3) the scale and timing of generic or biosimilar-like price pressure where permitted. The company-level revenue impact is increasingly tied to mix (dose penetration and duration), contract pricing, and channel inventory rather than pure patient growth.

What is VICTOZA and what market does it compete in?

VICTOZA is a once-daily GLP-1 receptor agonist (liraglutide) indicated for:

• Type 2 diabetes mellitus (T2DM), including to improve glycemic control
• Reducing the risk of major cardiovascular events in adults with T2DM and established cardiovascular disease or at high cardiovascular risk (where approved)
• Chronic weight management is not an original VICTOZA indication in the US; weight-management dosing is associated with liraglutide’s obesity product under a different brand/labeling.

GLP-1 competitive set

VICTOZA’s competitive field now spans multiple GLP-1 molecules and schedules:

• Once-weekly GLP-1s (key share challengers for convenience and weight-loss strength)
• Fixed-dose GLP-1 and dual-agonist products (where payers steer toward broader cardiometabolic claims)
• Regional differences in preferred-in-class status and reimbursement rules

---

How has VICTOZA sales evolved and what are the main drivers of revenue changes?

VICTOZA’s revenue pattern in mature markets is shaped by three macro drivers:

1. Patient share migration to newer GLP-1s

   • Prescriber adoption has shifted toward once-weekly agents with stronger weight-loss outcomes and simplified regimens.
   • The clinical differentiation that still favors certain subpopulations does not stop overall class substitution in most payer structures.

2. Payer contracting and step edits

   • Formularies increasingly use step therapy, prior authorization, and quantity controls to direct demand to the most cost-effective preferred product.
   • Net price volatility rises as wholesalers and health systems manage inventory ahead of expected competitive entry.

3. Mix and dosing durability

   • VICTOZA economics depend on how many patients titrate to and sustain the therapeutic dose.
   • Contract terms often reward volume and adherence, creating both upside (retention) and downside (switching when preferred alternatives become cheaper or offer better rebates).

Financial trajectory by “stage of lifecycle”

• Early-to-mid growth phase: driven by diabetes expansion, formulary wins, and limited alternatives.
• Mature phase: growth increasingly comes from dose optimization and persistence rather than new patient starts.
• Competitive erosion phase: starts decline as newer GLP-1s take first-line or preferred positions and as payers broaden coverage criteria for competitors.

---

Why is VICTOZA losing market share: which dynamics are steering switches?

The main switching catalysts for GLP-1 prescribers and payers are operational and outcome-based:

• Dosing schedule

  • Once-weekly regimens reduce injection burden and can improve adherence.
  • Convenience becomes a payer-friendly argument for preferred positioning.

• Weight-loss and cardiometabolic performance

  • Payers and prescribers increasingly treat obesity and cardiometabolic risk as a major value framework, not only glycemic control.
  • Competing agents with stronger weight-loss labeling and/or evidence shift clinician and patient expectations.

• Commercial strategy and contracting

  • Rebates and access agreements concentrate demand on one or two “preferred” GLP-1s per plan.
  • As those preferred products gain traction, switching becomes a low-friction administrative pathway in practice.

Clinical and economic segmentation that still supports VICTOZA

• Patients stabilized on liraglutide who remain adherent
• Regions and plans with long-standing VICTOZA coverage and rebate structures
• Subgroups where formulary alternatives are constrained by intolerance, contraindications, or coverage barriers

---

What is the exclusivity and patent-expiration timeline for VICTOZA, and when does exclusivity lose leverage?

VICTOZA’s exclusivity timeline is assessed through two layers:

1. Patent term and patent-specific expiration for active ingredient, composition, and method-of-use claims
2. Regulatory exclusivity (where applicable) tied to original approvals and changes in labeling or supplemental approvals

For a litigation and licensing risk view, the relevant question is not only when the “last” patent expires, but whether claims remain enforceable that cover:

• dosing regimens (method-of-use)
• specific patient subsets
• formulations or delivery devices
• manufacturing processes

What this means for future generic or lower-priced entry

• If method-of-use claims remain, generics may face launch restrictions or require labeling carve-outs.
• If formulation or device claims survive, “drop-in” substitutions can be slower or require design-around.

---

What is the Orange Book status of VICTOZA, and how does it shape generic entry risk?

Orange Book listing status is the practical screen for:

• whether ANDA sponsors can challenge based on eligible patents
• whether the risk is “full” (easy launch) or “partial” (labeling carve-out or injunction risk)

Key commercial implication:

• As Orange Book-listed patents mature, the window for generic entry becomes more credible.
• If remaining listed patents are method-of-use or layered, generic entry can still occur but with constrained labeling, limiting immediate market disruption.

---

How do Paragraph IV ANDA challenges change the financial outlook for VICTOZA?

Where ANDA challengers target Orange Book-listed patents covering the core protected claims, the commercial impact typically shows up as:

• pre-launch price negotiations and rebate adjustments
• heightened contracting intensity from the reference product
• increased substitution in formularies near anticipated court decisions

A Paragraph IV event typically creates a “decision-year” that markets and payers use to prepare:

• who gets preferred status
• whether to tighten step therapy
• how to handle substitution switching programs

Litigation outcomes that change economics most

• Final validity findings that clear the path for launch
• Settlement agreements that delay entry or cap generic labeling
• Injunction orders that pause lower-priced supply

---

Is VICTOZA exposed to biosimilar-like risk, or is the threat purely generic?

VICTOZA is a small-molecule GLP-1 receptor agonist, so the competitive threat is primarily generic ANDA entry, not biosimilars. The operative risk is:

• chemical equivalence enabling substitution
• patent landscape determining timing of “true” label-aligned entry
• device- and method-of-use claim enforceability shaping launch scope

---

What formulations or delivery-device patents affect substitution and price erosion?

VICTOZA’s product economics also depend on whether any patents remain for:

• pen injector design or usability components
• manufacturing process parameters
• formulation composition that improves stability or tolerability

If such patents persist, a competitor may:

• launch with design-around devices
• be delayed if the design-around still infringes
• accept labeling constraints that slow uptake

---

Which companies compete with VICTOZA and how do their product economics compare?

VICTOZA faces competition mainly from:

• newer GLP-1s with once-weekly dosing
• GLP-1 products with stronger weight-loss positioning
• combination incretin approaches where available

Competitive pressure channels

• Formulary preference: preferred product locks in share unless plan rules change
• Channel contracting: health systems negotiate discounts tied to volume
• Patient affordability programs: coupon programs can temporarily protect demand but often lose impact when payers standardize coverage

---

What revenue exposure does VICTOZA face across geographies?

VICTOZA’s financial trajectory differs by region due to:

• how quickly formularies adopt the newest GLP-1s
• patent validity and enforcement strength
• reimbursement systems and automatic substitution rules
• local competitor penetration and pricing

In markets where newer GLP-1s were launched earlier and achieved preferred status faster, the erosion tends to be more pronounced and earlier. In markets with slower adoption, VICTOZA can maintain higher persistence.

---

What commercial levers can extend VICTOZA earnings as competition intensifies?

Reference-product strategies that typically protect cash flow in mature GLP-1 franchises:

• contract pricing and rebate restructuring tied to access
• line-extension strategies where permitted by label and manufacturing capacity
• patient support programs targeting persistence and adherence
• targeted contracting with large payers and pharmacy benefit managers

What does “successful defense” look like?

• retention of a substantial share of treated patients
• reduced net price decline despite contracting pressure
• minimization of switch-rate acceleration around competitor formulary updates

---

What litigation or settlement activity would most impact VICTOZA’s future economics?

The largest revenue inflection points generally come from:

• court decisions clearing or upholding key Orange Book patents
• settlements that set generic launch dates or provide carve-outs
• consent decrees that allow early entry with limited labeling

Even without an immediate entry, adverse decisions can trigger payer re-contracting and increase substitution readiness.

---

How should investors and business planners model VICTOZA’s forward financial trajectory?

A practical model for VICTOZA’s next phase typically tracks:

• volume: new starts, switch rates, and persistence
• mix: dose titration and duration on therapy
• net price: rebate and discount changes
• timing: milestone-driven shifts tied to patent/ANDA outcomes and payer formulary reviews
• geography: faster erosion markets vs slower adoption markets

The core expectation is usually:

• declining new patient growth
• persistence-supported revenue until competitive preference becomes entrenched
• step-change downside if full label-aligned generic entry clears key patents in major markets

---

Key Takeaways

• VICTOZA’s revenue trajectory is dominated by class substitution to newer GLP-1s, payer formulary design, and persistence-driven mix rather than new patient expansion.
• Exclusivity and Orange Book status control generic and litigation timing, which in turn affects net price through contracting behavior ahead of entry.
• Because VICTOZA is a small molecule, generic ANDA risk drives substitution scenarios; biosimilar risk is not the relevant mechanism.
• Forward financial outcomes hinge on switch rates, contract pricing, and whether remaining protected claims delay label-aligned competition.

---

FAQs

1) What payer formulary designs most quickly reduce VICTOZA share?
Plans that impose step edits, restrict access to preferred products, and implement automatic prior authorization rules tied to clinical criteria.

2) Does VICTOZA face a faster erosion risk than other GLP-1s?
Relative erosion accelerates when competitors achieve preferred formulary status earlier and when payers emphasize weight-loss or broader cardiometabolic endpoints.

3) How does dosing convenience influence switching from VICTOZA?
Once-weekly schedules reduce injection frequency and typically increase adherence, strengthening payer and prescriber preference over time.

4) What patent claim types matter most for generic launch timing of VICTOZA?
Method-of-use and labeling-linked patents can delay meaningful substitution even if chemical composition patents have matured.

5) What commercial events typically precede a visible VICTOZA sales decline?
Contract renegotiations, formulary updates, and pharmacy benefit manager (PBM) re-pricing that favors alternate GLP-1s ahead of anticipated competitive entry.

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA Drug Label Information for VICTOZA (liraglutide). U.S. Food and Drug Administration.
3. FDA ANDA Guidance and Paragraph IV Framework. U.S. Food and Drug Administration.

DrugChatter Q&A for VICTOZA

Victoza patent expiration november 2024?
Victoza loss of exclusivity?
Victoza patent november 2024?
Victoza prescribing trends physicians glp 1 agonist liraglutide market share primary care endocrinology?
Victoza market exclusivity period?